Literature DB >> 26528641

Antipsychotic treatment of adults in the United States.

Mark Olfson1, Marissa King, Michael Schoenbaum.   

Abstract

OBJECTIVE: Despite safety risks associated with antipsychotic medications, little is known about their use in older adults. This article describes patterns of antipsychotic treatment of older and younger adults in the United States.
METHOD: The IMS LifeLink LRx Longitudinal Prescription database was analyzed retrospectively, focusing on adults who filled antipsychotic prescriptions. The database was searched for the years 2006 and 2008-2010. Denominators were adjusted to generalize annual antipsychotic use percentages by sex and single year of age to the US population. Among adults with any antipsychotic use, percentages with short-term (≤ 30 days) and long-term (≥ 120 days) use, prescriptions from psychiatrists, use of other psychotropic medication classes, and ICD-9 clinical diagnoses were also evaluated.
RESULTS: The percentages of US adults by age group who used antipsychotics in 2010 were 0.93% (20-34 years), 1.46% (35-59 years), 1.54% (60-64 years), 1.36% (65-69 years), 1.36% (70-74 years), 1.58% (75-79 years), and 2.09% (80-84 years). Women were consistently more likely than men to use antipsychotics. The percentages of antipsychotic-treated older adults with long-term use were 53.7% (70-74 years), 49.2% (75-79 years), and 46.2% (80-84 years). Among adults with any antipsychotic use, percentages with prescriptions from psychiatrists decreased with age from 66.2% (20-34 years) to 20.6% (80-84 years). Dementia was commonly diagnosed among antipsychotic-treated adults aged 75-79 years (37.2%) and 80-84 years (47.8%) who had any mental disorder or dementia diagnoses.
CONCLUSIONS: Despite concerns over the safety of antipsychotic treatment of older adults, long-term use is common. Key challenges for clinical research and practice include development and implementation of management strategies for older adults that are safer than antipsychotic medications. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26528641     DOI: 10.4088/JCP.15m09863

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

1.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

2.  Predictors of Calf Arterial Compliance in Male Veterans With Psychiatric Diagnoses.

Authors:  Maju Mathew Koola; John D Sorkin; Molly Fargotstein; W Virgil Brown; Bruce Cuthbert; Jeffrey Hollis; Jeffrey K Raines; Erica J Duncan
Journal:  Prim Care Companion CNS Disord       Date:  2016-06-09

3.  Care Pathways Before First Diagnosis of a Psychotic Disorder in Adolescents and Young Adults.

Authors:  Gregory E Simon; Christine Stewart; Enid M Hunkeler; Bobbi Jo Yarborough; Frances Lynch; Karen J Coleman; Arne Beck; Belinda H Operskalski; Robert B Penfold; David S Carrell
Journal:  Am J Psychiatry       Date:  2018-01-24       Impact factor: 18.112

4.  Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole.

Authors:  H Oughli; E J Lenze; A E Locke; M D Yingling; Y Zhong; J P Miller; C F Reynolds; B H Mulsant; J W Newcomer; T R Peterson; D J Müller; G E Nicol
Journal:  J Psychiatr Res       Date:  2019-04-23       Impact factor: 4.791

5.  Smoking Cessation and Electronic Cigarettes in Community Mental Health Centers: Patient and Provider Perspectives.

Authors:  Li-Shiun Chen; Timothy Baker; Ross C Brownson; Robert M Carney; Douglas Jorenby; Sarah Hartz; Nina Smock; Mark Johnson; Douglas Ziedonis; Laura J Bierut
Journal:  Community Ment Health J       Date:  2016-11-30

6.  Use of Antipsychotic Drugs During Pregnancy.

Authors:  Hannah K Betcher; Catalina Montiel; Crystal T Clark
Journal:  Curr Treat Options Psychiatry       Date:  2019-01-30

Review 7.  Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.

Authors:  Mahmoud Slim; Inmaculada Medina-Caliz; Andres Gonzalez-Jimenez; M Rosario Cabello; Fermin Mayoral-Cleries; M Isabel Lucena; Raul J Andrade
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

8.  Validation of Random Forest Machine Learning Models to Predict Dementia-Related Neuropsychiatric Symptoms in Real-World Data.

Authors:  Javier Mar; Ania Gorostiza; Oliver Ibarrondo; Carlos Cernuda; Arantzazu Arrospide; Álvaro Iruin; Igor Larrañaga; Mikel Tainta; Enaitz Ezpeleta; Ane Alberdi
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

9.  Using Open Questions to Understand 650 People's Experiences With Antipsychotic Drugs.

Authors:  John Read; Ann Sacia
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

10.  Use of antipsychotics and the risk of acute respiratory failure among adults: A disease risk score-matched nested case-control study.

Authors:  Meng-Ting Wang; Chen Wei Lin; Chen-Liang Tsai; Yun-Han Wang; Jyun-Heng Lai; Chin-Bin Yeh; Ya-Ling Huang; Yu-Juei Hsu
Journal:  Br J Clin Pharmacol       Date:  2020-05-30       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.